Company intelligence / Profile preview
Ocugen
Malvern, Pennsylvania, United Statesocugen.com ↗
- Ownership
- Public · OCGN
- Employees
- ~200
- Development stage
- Phase 3
01
Overview
Ocugen has advanced a pipeline of novel gene therapies targeting rare retinal diseases with no current treatments. Its lead asset OCU410ST for Stargardt disease will enter a pivotal Phase 2/3 trial after FDA alignment. Early clinical data across its three main clinical-stage programs show stabilization or improvement in vision with favorable safety profiles. The company also develops cell therapies for orthopedic conditions and inhaled vaccines against COVID‑19 and flu.
- Therapeutic areas
- OphthalmologyInfectious DiseasesRheumatology
- Modalities
- Gene therapy (AAV-based modifier gene therapy)Cell therapy (autologous chondrocyte-derived neocartilage)Vaccines (inhaled and traditional)Biologics
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
Collaboration with NIAID on inhaled vaccine development
04
Financials
- Market cap
- $451M
- Total revenue
- $1.5M
- Enterprise value
- $439M
Beyond the preview
Go deeper on Ocugen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ocugen.